Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
L Emmett, K Willowson, J Violet, J Shin… - Journal of medical …, 2017 - Wiley Online Library
Prostate‐specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer
cells that is revolutionising the way we image and treat men with prostate cancer. New small …
cells that is revolutionising the way we image and treat men with prostate cancer. New small …
Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
MP Yadav, S Ballal, RK Sahoo… - American Journal of …, 2019 - Am Roentgen Ray Soc
OBJECTIVE. Several clinical studies have shown the efficacy of 177Lu-labeled prostate-
specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration …
specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration …
German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients
K Rahbar, H Ahmadzadehfar… - Journal of Nuclear …, 2017 - Soc Nuclear Med
177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy
(RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by …
(RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by …
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
WP Fendler, M Eiber, M Beheshti, J Bomanji… - European journal of …, 2017 - Springer
The aim of this guideline is to provide standards for the recommendation, performance,
interpretation and reporting of 68 Ga-PSMA PET/CT for prostate cancer imaging. These …
interpretation and reporting of 68 Ga-PSMA PET/CT for prostate cancer imaging. These …
[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Summary Background Lutetium-177 [177 Lu] Lu-PSMA-617 is a radiolabelled small
molecule that delivers β radiation to cells expressing prostate-specific membrane antigen …
molecule that delivers β radiation to cells expressing prostate-specific membrane antigen …
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, R Baum… - European journal of …, 2019 - Springer
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can
be identified by PSMA-ligand imaging, which has already become clinically accepted in …
be identified by PSMA-ligand imaging, which has already become clinically accepted in …
[HTML][HTML] Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer
A Paschalis, B Sheehan, R Riisnaes, DN Rodrigues… - European urology, 2019 - Elsevier
Background Prostate-specific membrane antigen (PSMA; folate hydrolase) prostate cancer
(PC) expression has theranostic utility. Objective To elucidate PC PSMA expression and …
(PC) expression has theranostic utility. Objective To elucidate PC PSMA expression and …
[HTML][HTML] Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, MS Hofman… - European journal of …, 2023 - Springer
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
Optimum imaging strategies for advanced prostate cancer: ASCO guideline
PURPOSE Provide evidence-and expert-based recommendations for optimal use of
imaging in advanced prostate cancer. Due to increases in research and utilization of novel …
imaging in advanced prostate cancer. Due to increases in research and utilization of novel …
PSMA theranostics: current status and future directions
K Rahbar, A Afshar-Oromieh, H Jadvar… - Molecular …, 2018 - journals.sagepub.com
Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics
and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases …
and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases …